

Compensation and Reimbursement

Pay-for-Performance Reimbursement (0708)

Source: Council on Pharmacy Management

To support pay-for-performance reimbursement models when they are appropriately structured to improve health care quality; further,

To oppose pay-for-performance reimbursement models that do not support an open culture of medication error reporting; further,

To encourage pharmacists to actively lead medication-related pay-for-performance initiatives.

Reimbursement for Unlabeled Uses of FDA-Approved Drug Products (0206)

Source: Council on Administrative Affairs

To support third-party reimbursement for FDA-approved drug products appropriately prescribed for unlabeled uses.

This policy was reviewed in 2006 by the Council on Pharmacy Management and by the Board of Directors and was found to still be appropriate.

Product Reimbursement and Pharmacist Compensation (0207)

Source: Council on Administrative Affairs

To pursue, in collaboration with public and private payers, the development of improved methods of reimbursing phar-

macies for the cost of drug products dispensed and associated overhead; further,

To educate pharmacists about those methods; further,

To pursue, with federal and state health-benefit programs and other third-party payers, the development of a standard mechanism for compensation of pharmacists for patient care services and compounding and dispensing services; further,

To pursue changes in federal, state, and third-party payment programs to (1) define pharmacists as providers of patient care and (2) issue provider numbers to pharmacists that allow them to bill for patient care services; further,

To educate and assist pharmacists in their efforts to attain provider status and receive compensation for patient care services.

This policy was reviewed in 2006 by the Council on Pharmacy Management and by the Board of Directors and was found to still be appropriate.